Oppenheimer & Co. Inc. Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Oppenheimer & Co. Inc. acquired a new stake in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 4,100 shares of the company’s stock, valued at approximately $227,000.

Several other institutional investors have also recently modified their holdings of TARS. Lisanti Capital Growth LLC bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at about $1,311,000. GSA Capital Partners LLP bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter valued at about $740,000. Mutual of America Capital Management LLC bought a new position in Tarsus Pharmaceuticals during the 3rd quarter worth approximately $4,291,000. Jennison Associates LLC increased its stake in Tarsus Pharmaceuticals by 47.2% in the 3rd quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after purchasing an additional 698,712 shares during the period. Finally, Intech Investment Management LLC purchased a new position in Tarsus Pharmaceuticals in the 3rd quarter worth approximately $282,000. 90.01% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

TARS has been the subject of a number of analyst reports. Oppenheimer increased their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group increased their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Barclays decreased their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group increased their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a report on Thursday. Finally, Guggenheim reiterated a “buy” rating and set a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $63.67.

Tarsus Pharmaceuticals Trading Up 6.7 %

Shares of TARS opened at $46.47 on Monday. Tarsus Pharmaceuticals, Inc. has a 1-year low of $20.08 and a 1-year high of $57.28. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -12.20 and a beta of 1.05. The firm’s 50-day moving average price is $49.97 and its 200-day moving average price is $44.00. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. Sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.